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ABSTRACT
Objective The objective of this article is to analyse the positive predictive value (PPV) of trisomies 21, 18 and 13 after
referral for advanced maternal age (AMA), first trimester combined test or ultrasound findings to suggest
improvements for clinical practice.
Methods Data (48 457 combined tests, 134 000 fetal anomaly scans and 24 379 invasive prenatal tests) were combined
to calculate PPV and termination of pregnancy rates.
Results For referral for AMA, the PPV for T21 was 1.0% and 1.8% for amniocentesis and chorionic villus biopsy,
respectively; for the combined test at a maternal age ≥36 years, these percentages were 4.9% and 12.5%, respectively
and for maternal age <36 years, 4.4% and 8.1%, respectively. For ultrasound findings, the PPV was 5.3% and 14.8%,
respectively. Termination of pregnancy rate upon trisomy 21 diagnosis was >90% unless detected after referral for
ultrasound findings (71.5–85.9%). About 50% of pregnant women with a high combined test risk chose not to have
invasive testing.
Conclusions Advanced MA is still a large contributor to invasive testing but should be abandoned (low PPV, high fetal
loss rate) and be replaced by reimbursable combined test screening for all women. Patient information on second
trimester ultrasound screening should indicate that abnormal ultrasound findings are associated with high trisomy
rate. © 2013 John Wiley & Sons, Ltd.
Funding sources: None
Conflicts of interest: None declared
INTRODUCTION
Invasive prenatal diagnosis for fetal trisomies is usually based
on advanced maternal age (AMA), first trimester screening or
abnormal ultrasound findings. However, data on the positive
predictive value (PPV) of these screening modalities and on
the resulting incidence of termination of pregnancy (TOP) in
case of a positive result are scattered. We previously addressed
these issues in a regional study in The Netherlands. These
studies showed that for referral for AMA, the PPV for trisomy
21 (T21) was 3%; for the combined test, it was 10% and for
second trimester ultrasound findings, it was 30%.1 We also
found that in this region, only 65% of all women with a high
combined test risk chose for an invasive test.2
We now report on the complete nationwide Dutch data
set from 2007 to 2009 to investigate PPV and TOP for
AMA, combined test and ultrasound findings. For this
purpose, we combined data from reports on first trimester
combined test and second trimester anomaly scans
within the Dutch prenatal screening programme and
data of annual reports on invasive testing. On the basis
of these findings, we provide suggestions to improve
clinical practice.
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MATERIAL AND METHODS
Organisation of the screening
Invasive prenatal testing for AMA was implicated in the Dutch
obstetric system since the early seventies. A more advanced
national programme for prenatal screening, consisting of two
tests, started in January 2007. The first is the combined test.
This test was initially performed as a risk calculation
specifically for the detection of T21 using maternal serum
concentrations of pregnancy-associated plasma protein A and
the free ß-subunit of human chorionic gonadotrophin between
9 and 13+6weeks of gestational age (GA), combined with first
trimester ultrasound measurement of the fetal nuchal
translucency (NT) and maternal age (cut-off risk allowing
invasive testing: 1 in 200). Risk calculation for trisomies 13
(T13) and 18 (T18) were only added in 2011. The second part of
the programme consists of a fetal anomaly ultrasound scan
between 18 and 22weeks of GA. Informed decision and
acknowledgement of the right not to be informed are hallmarks
of the programme; the offer to be informed on the possibilities
of prenatal screening ismandatorywithin the programme.When
a woman decides to receive information on screening tests, she
can opt in or out for either or both tests. Insurance companies
reimburse the costs (€155) for the ultrasound scan for women
of all ages, whereas the first trimester combined test (€155) is
reimbursed only for women of 36 years and older. Moreover,
the latter group can still directly opt for invasive prenatal testing
[i.e. amniocentesis (AC) or chorionic villus biopsy (CVS)],
whereas younger women cannot. Invasive prenatal diagnosis
and karyotyping in The Netherlands is by law strictly assigned
to eight universitymedical centres, all with their assigned regions
and together covering the entire country.
Origin of data
Complete annual data of the first trimester combined test (both
demographic and pregnancy-related data, concentrations
and MoM values of the biochemical parameters and NT
measurements) were derived from the annual reports of the
screening laboratories.3 Summarised data on the anomaly scan
(numbers of anomaly scans in each region) were derived from
an annual report.4 Complete annual data on invasive prenatal
testing were derived from the 2006 to 2009 annual reports of
the Working Group on Prenatal Diagnosis and Therapy (WPDT)
of jointly the Dutch Association for Obstetrics and Gynaecology
and the Dutch Society for Clinical Genetics.
Study design
Annual numbers of AC and CVS stratified for the reasons for
referral were derived from the annual reports of the WPDT.
The reasons for referral were (1) AMA, (2) high risk in
combined test in women younger than 36 years, (3) high risk
in combined test in women 36 years and older. Other referral
categories were split up to produce a category for (4)
ultrasound findings and (5) miscellaneous (consisting of five
small referral categories; for example, previous chromosomal
finding or neural tube defect in parents or siblings and
previous aberrant genetic or biochemical result). Furthermore,
the WPDT reports contain the results of the invasive tests in
the referral categories AMA, combined test in women younger
than 36 years, combined test in women 36 years and older and
a referral category ‘not AMA or combined test’, which contains
virtually all T21,T18 and T13 cases detected because of a
referral after an abnormal ultrasound finding. Finally, the
WPDT reports contained the numbers of pregnancies that
were terminated after diagnosis. Our study reports on the
results for T21, 18 and 13. Data were combined to determine
the numbers of invasive tests performed (stratified for referral
category and procedure; AC or CVS), PPV (expressed as the
percentage of abnormal karyotype per invasive procedure
performed), as well as the rates of TOP per referral category.
To indicate statistically significant differences between
referral categories or year, data were expressed as percentages
with 95% confidence intervals (CIs).
Although only completely anonymised, accumulated and
published data were used for this study, no approval by a
medical ethical committee was needed.
RESULTS
To obtain a complete view on invasive testing after the start of
the programme in 2007, a summary of data on invasive tests
and referral categories is given in Table 1. There was not a clear
trend in the total number of invasive procedures between 2007
and 2009. Expressed as proportion of the total Dutch birth
rate, however, there was a small decrease in 2009 (4.2%
compared with 4.5% in 2007–2008). Roughly two-thirds of the
invasive tests consisted of AC, a percentage that did not
change over time and varied between centres from 40% to
87% (data not shown).
The proportion of invasive testing for AMA decreased from
53.8% to 48.8% between 2007 and 2009, with a concomitant
small increase of the proportion of referrals for combined test
(from 16.3% to 18.9%) and ultrasound findings (from 16.7% to
18.9%). Referrals for ultrasound findings were followed by an
AC (increasing from 67.2% to 72.8%) or by a CVS (decreasing
from 32.8% to 27.2%).
Table 2 summarises the PPV per referral category for 2007 to
2009, for T21 and all major trisomies combined (T21, T18 and
T13). Referrals based on AMA followed by AC had a fourfold
lower chance of showing a case of T21 compared with referrals
based on combined test screening for women ≥36years of
age or ultrasound findings (PPV: 1.0%, 4.9% and 5.3%,
respectively). For CVS, these differences were even more
pronounced; AMA was about seven times less effective than
combined test screening and about nine times less effective than
ultrasound abnormalities (PPV 1.8%, 12.5% and 14.8%,
respectively). For T21, T18 and T13 combined, the PPV after
CVS for AMA, combined test ≥36years of age and ultrasound
findings were 2.6%, 17.3% and 29.2%, respectively. The PPV after
referral for combined test was in general higher for the age group
≥36years as compared with <36years. Notably, the PPV to
detect a T21, T18 or T13 after referral for ultrasound findings
(12.7% after AC and 29.2% after CVS) was about twice the PPV
after referral for combined screening ≥36 years (6.0% and
J. E. Siljee et al.260
Prenatal Diagnosis 2014, 34, 259–264 © 2013 John Wiley & Sons, Ltd.
17.3%, respectively). In all categories, the PPV for trisomies was
two to three times higher in the CVS group as compared with AC.
T21 TOP rates were nearly 90% or higher for all categories of
referrals except for ultrasound findings, where the TOP rate
was distinctively lower (Table 3). There were too few cases of
T18 and T13 to draw conclusions from.
DISCUSSION
In this study, we combined the data of 3 years of screening in The
Netherlands after the introduction of a new prenatal screening
policy by evaluating PPV of various referral categories and data
on TOP after invasive testing. It is of interest that the
introduction of the nationwide screening programme in The
Netherlands in 2007 hardly resulted in changes in absolute
or relative numbers per referral category for invasive testing
(Table 1). During this study period, T18 and T13 risks were
not yet reported as part of the combined test, but even so,
the combined test picked up a fair number of T18 and T13
cases. This is in agreement with our previous report on T13
and T18 detection with the combined test.5
The percentage of invasive tests because of AMA alone
remained high between 2007 and 2009 (Table 1). However,
Table 1 Number of invasive tests per referral category and type of invasive test [amniocentesis (AC) or chorionic villus biopsy (CVS)] in
The Netherlands, 2007 to 2009
2007 2008 2009 2007–2009
Birth ratea 181 336 184634 184915 550885
Total number of invasive tests (% of birth rate, CI) 8225
4.5 (4.4, 4.6)
8341
4.5 (4.4, 4.6)
7813
4.2 (4.1, 4.3)
24379
4.4 (4.4, 4.4)
Number of AC (%; CI) 5487
66.7 (65.7, 67.7)
5525
66.2 (65.2, 67.2)
5183
66.3 (65.3, 67.4)
16195
66.4 (65.8, 67)
Number of CVS (%; CI) 2738
33.3 (32.3, 34.3)
2816
33.8 (32.8, 34.8)
2630
33.7 (32.6, 34.7)
8184
33.6 (33, 34.2)
Referral for (N and as % of total number of AC/CVS)
Maternal age 4424
53.8 (52.7, 54.9)
4259
51.1 (50, 52.1)
3812
48.8 (47.7, 49.9)
12495
51.3 (50.6, 51.9)
AC (%; CI) 3126
70.7 (69.3, 72)
2962
69.5 (68.1, 70.9)
2648
69.5 (68, 70.9)
8736
69.9 (69.3, 70.9)
CVS (%; CI) 1298
29.3 (28, 30.7)
1297
30.5 (29.1, 31.9)
1164
30.5 (29.1, 32)
3759
30.1 (29.3, 30.9)
Combined test age ≥36 years 717
8.7 (8.1, 9.3)
777
9.3 (8.7, 10)
789
10.1 (9.4, 10.8)
2283
9.4 (9, 9.7)
AC (%; CI) 492
68.6 (65.1, 71.9)
510
65.6 (62.2, 68.9)
533
67.6 (64.2, 70.7)
1535
67.2 (65.3, 69.1)
CVS (%; CI) 225
31.4 (28.1, 34.9)
267
34.4 (31.1, 37.8)
256
32.4 (29.3, 35.8)
748
32.8 (30.9, 34.7)
Combined test age <36 years 625
7.6 (7, 8.2)
695
8.3 (7.8, 8.9)
687
8.8 (8.2, 9.4)
2007
8.2 (7.9, 8.6)
AC (%; CI) 400
64.0 (60.2, 67.7)
450
64.7 (61.1, 68.2)
423
61.6 (57.9, 65.1)
1273
63.4 (59.5, 63.7)
CVS (%; CI) 225.00
36 (32.3, 39.8)
245.00
35.3 (31.8, 38.9)
264.00
38.4 (34.9, 42.1)
734.00
36.6 (34.5, 38.7)
Ultrasound findings 1377
16.7 (16, 17.6)
1550
18.6 (17.8, 19.4)
1465
18.8 (17.9, 19.6)
4392
18 (17.5, 18.5)
AC (%; CI) 925
67.2 (64.7, 69.6)
1097
70.8 (68.5, 73)
1066
72.8 (70.4, 75)
3088
70.3 (68.9, 71.6)
CVS (%; CI) 452
32.8 (30.4, 35.3)
453
29.2 (27, 31.5)
399
27.2 (25, 29.6)
1304
29.7 (28.4, 31.1)
Miscellaneous 1082
13.2 (12.4, 13.9)
1060
12.7 (12, 13.4)
1060
13.6 (12.8, 14.3)
3202
13.1 (12.7, 13.6)
AC (%; CI) 544
50.3 (47.3, 53.3)
506
47.7 (44.7, 50.7)
513
48.4 (45.4, 51.4)
1563
48.8 (47.1, 50.5)
CVS (%; CI) 538
49.7 (46.7, 52.7)
554
52.3 (49.3, 55.3)
547
51.6 (48.6, 54.6)
1639
51.2 (49.5, 52.9)
CI, confidence interval.
Data in the table are absolute numbers and proportions with 95% CI.
The composition of the category ‘miscellaneous’ is described in the Materials and Methods Section.
aBirth rates are from Statistics Netherlands (www.cbs.nl., accessed 3/8/13).
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the incidence of diagnosed cases of T21 with an AP was
fourfold and with a CVS was up to sevenfold lower that of
referral for a combined test high risk (Table 2). Published data
on the comparison of PPV for AMA and combined test in
routine screening programmes are scarce, but these data are
in agreement with those or an earlier regional study in The
Netherlands.1 We previously have reported on the costs and
effects of various screening scenarios in The Netherlands.6
Although a detailed cost-effectiveness analysis is beyond the
scope of this article, a rough estimate learns that replacing all
AMA by combined tests would save 75% of the costs. The
detected fetal loss to detected T21 case rate would be one loss
for every two detected for AMA referral and 1 loss for every 15
detected for the combined test. So, there are many reasons to
abandon screening on the basis of AMA. In anticipation of the
notion that referral for AMA is suboptimal, the coordinating
committee of the Dutch Down syndrome screening programme
did send an advice to theMinister of Health in December 2011 to
abolish AMA as an indication for invasive testing and tomake the
costs of the combined test reimbursable for women younger
than 36 years as well.
The PPV for aneuploidies at karyotyping after AC or CVS after
referral for abnormal ultrasound findings were the highest of all
screening tests; the PPV to pick up any trisomy after a referral
for abnormal ultrasound findings was 29.2%, so nearly one out
of three (Table 2). A relatively small fraction of referrals for
ultrasound findings may have consisted of anomalies discovered
in the first trimester,mainly because of the fact that a few patients
were referred immediately after a largeNTmeasurement, without
performing a serum analysis for the combined test. The vast
majority of all referrals for abnormal ultrasound findings were,
however, because of an 18 to 22-week screening anomaly scan
(which was performed in at least 80% of the pregnant population
in 2009) and about 15000-s expert structural anomaly scans for
enhanced risk for fetal structural anomalies.4 Also, in our previous
study concerning a regional screening programme, ultrasound
examinations were mostly second trimester scans.1
The anomaly scan was introduced in the Dutch screening
programme as a screening test for structural anomalies,
specifically neural tube defects, not as a screening test for
aneuploidies. The data of this study show however that the
anomaly scan, both in terms of PPV and absolute numbers, is
Table 2 Positive predictive value (and confidence interval) for T21
and for T13, T18 and T21 combined after amniocentesis (AC) or
chorionic villus biopsy (CVS) for 2007 to 2009 combined
Referral for T21 T21-18-13-combined
Maternal age AC 1.0 (0.8–1.2) 1.3 (1.1–1.6)
CVS 1.8 (1.4–2.2) 2.6 (2.1–3.1)
Combined test age
≥36 years
AC 4.9 (4.0–6.1) 6.0 (4.9–7.3)
CVS 12.5 (10.4–15.0) 17.3 (14.8–20.1)
Combined test age
<36 years
AC 4.4 (3.4–5.6) 4.7 (3.7–6.0)
CVS 8.1 (6.4–10.3) 10.8 (8.8–13.3)
Ultrasound findings AC 5.3 (4.6–6.2) 12.7 (11.6–13.9)
CVS 14.8 (13.0–16.8) 29.2 (26.9–31.7)
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superior to the combined test to pick up T21, T18 and T13. This
does not imply that the anomaly scan is a good screening test
for T21, as we do not know the number of T21 cases missed by
the anomaly scan, nor do we know how many pregnant women
with abnormal ultrasound findings opt out for invasive prenatal
diagnosis. Presently, the patient information leaflet does not
mention that many genetic abnormalities are discovered by the
anomaly scan. On the basis of the present data, we advise to
counsel an abnormal karyotype, especially the common
aneuploidies, as an unexpected finding.
In a previous report on TOP rates for detected trisomies in The
Netherlands between 1991 and 2000, 88% of T21, 79% of T18 and
81% of T13 pregnancies were terminated.7 A study reviewing a
large cohort of the UK data also showed TOP rates for T21
pregnancies of 81%.8 A recent Canadian study showed a TOP rate
of 66.7% and included a review of the literature showing a TOP
rate of 70% to 100%.9 The TOP rates of the current study
generallymatch both the historical Dutch data aswell as the data
from other countries. It appeared that TOP rates after AC
because of referral for ultrasoundfindings were lowest of all. This
could be due to the fact that the anomaly scan was aimed at
detecting ultrasound abnormalities and not at detecting
aneuploidies as a primary outcome, being ‘unexpected findings’.
Additionally, these TOP may be pushed too much towards the
legally accepted GA for TOP in The Netherlands (until 23weeks
and 6days) as well. Both facts might not warrant TOP for this
subgroup of pregnant women. Other reasons, for example,
emotional reasons and the expectancy of the natural demise of
these pregnancies, could also play a role. A higher uptake of first
trimester screening may well avoid some of these problems.
The percentage of high-risk results for the Down syndrome
screening in 2009 was 6.2% (CI: 5.9–6.5%) of a total of 48 457
tests3 or 3005 (CI: 2854–3161) referrals. The actual number of
invasive tests was only 1476 (Table 1). This indicates that about
50% of pregnant women with high-risk results after a
combined test still decide to opt out for a diagnostic test. This
is in line with the previously published 65% opting out in a
regional Dutch population2 and with 49.3% in a recent
Canadian study.9 A detailed analysis of which women with
high risks opt out for invasive testing, possibly explaining part
of this phenomenon, was published recently.2
The strength of this article is the large and nationwide data
set. A shortcoming is the inability to exactly quantify the
number of first versus second trimester referrals for abnormal
ultrasound findings. Moreover, the total number of referrals
for abnormal ultrasound findings was not completely clear in
all cases, because we assumed that among the referrals other
than combined test or AMA, reported T21,T18 and T13 cases
were mostly from referrals for ultrasound findings (other
referral categories were shown to detect virtually no T21, T18
or T13). It would be of interest to analyse the results of all
referral categories in relation to the MA at prenatal diagnostic
test, but these data are currently not available. Thus, there is
still room for improvement in registration.
In conclusion, invasive prenatal diagnosis based on AMA
alone is still a large contributor to invasive testing. However,
given its low PPV, high fetal loss rate and high costs, this
indication should be abandoned and be replaced by first
trimester screening free of charge for all women. The presence
of fetal abnormalities at second trimester ultrasound scan had
the highest detection rate of trisomy but is unlikely to replace
first trimester screening because false negatives are unknown,
because trisomy detection is currently not the main reason
for such a scan and because a diagnosis is usually made
rather late.
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WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• Reports on positive predictive value and termination of pregnancy
rates of nationwide routine screening programmes do exist but
are scarce.
WHAT DOES THIS STUDY ADD?
• This is one of the very few reports on an entire nationwide screening
programme that presents data on positive predictive value and
termination of pregnancy rates after referral for advanced maternal
age, first trimester combined test and referral for ultrasound findings.
This study provides evidence that screening for advanced maternal
age should be abandoned.
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